John C.K. Iv Milligan Sells 258,000 Shares of TherapeuticsMD Inc (TXMD) Stock

TherapeuticsMD Inc (NASDAQ:TXMD) insider John C.K. Iv Milligan sold 258,000 shares of the firm’s stock in a transaction dated Thursday, December 6th. The stock was sold at an average price of $4.77, for a total transaction of $1,230,660.00. Following the sale, the insider now owns 1,601,419 shares of the company’s stock, valued at approximately $7,638,768.63. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

John C.K. Iv Milligan also recently made the following trade(s):

  • On Tuesday, December 4th, John C.K. Iv Milligan sold 129,000 shares of TherapeuticsMD stock. The stock was sold at an average price of $4.98, for a total transaction of $642,420.00.
  • On Thursday, November 29th, John C.K. Iv Milligan sold 258,128 shares of TherapeuticsMD stock. The stock was sold at an average price of $4.96, for a total transaction of $1,280,314.88.
  • On Thursday, November 15th, John C.K. Iv Milligan sold 258,000 shares of TherapeuticsMD stock. The stock was sold at an average price of $4.90, for a total transaction of $1,264,200.00.
  • On Wednesday, October 24th, John C.K. Iv Milligan sold 250,000 shares of TherapeuticsMD stock. The stock was sold at an average price of $5.35, for a total transaction of $1,337,500.00.
  • On Wednesday, October 10th, John C.K. Iv Milligan sold 250,000 shares of TherapeuticsMD stock. The stock was sold at an average price of $5.85, for a total transaction of $1,462,500.00.
  • On Wednesday, September 26th, John C.K. Iv Milligan sold 125,000 shares of TherapeuticsMD stock. The stock was sold at an average price of $6.78, for a total transaction of $847,500.00.
  • On Tuesday, September 11th, John C.K. Iv Milligan sold 250,000 shares of TherapeuticsMD stock. The stock was sold at an average price of $6.10, for a total transaction of $1,525,000.00.

Shares of TherapeuticsMD stock opened at $4.53 on Friday. TherapeuticsMD Inc has a twelve month low of $4.30 and a twelve month high of $7.66. The company has a quick ratio of 7.15, a current ratio of 7.23 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -12.24 and a beta of 1.35.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Wednesday, November 7th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.06. TherapeuticsMD had a negative net margin of 757.59% and a negative return on equity of 102.15%. The business had revenue of $3.47 million during the quarter, compared to analysts’ expectations of $4.43 million. During the same quarter in the previous year, the company earned ($0.07) EPS. The business’s revenue was down 21.5% on a year-over-year basis. As a group, equities research analysts expect that TherapeuticsMD Inc will post -0.58 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the business. Stevens Capital Management LP bought a new position in TherapeuticsMD in the 3rd quarter valued at about $101,000. B. Riley Wealth Management Inc. bought a new position in TherapeuticsMD in the 3rd quarter valued at about $102,000. Managed Account Services Inc. bought a new position in TherapeuticsMD in the 3rd quarter valued at about $117,000. Twin Focus Capital Partners LLC bought a new position in TherapeuticsMD in the 2nd quarter valued at about $187,000. Finally, NumerixS Investment Technologies Inc bought a new position in TherapeuticsMD in the 2nd quarter valued at about $218,000. 72.66% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have weighed in on the stock. BidaskClub cut shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research note on Saturday. Cantor Fitzgerald reiterated an “overweight” rating on shares of TherapeuticsMD in a research note on Friday, November 23rd. Oppenheimer set a $14.00 price objective on shares of TherapeuticsMD and gave the stock a “buy” rating in a research note on Wednesday, November 7th. Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Friday, November 2nd. Finally, ValuEngine cut shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a research note on Monday, October 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. TherapeuticsMD presently has an average rating of “Buy” and an average target price of $13.45.

ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/12/08/john-c-k-iv-milligan-sells-258000-shares-of-therapeuticsmd-inc-txmd-stock.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

See Also: What strategies should day traders use to execute a trade?

Insider Buying and Selling by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply